Efficacy of cefditoren in the treatment of upper respiratory tract infections: A pooled analysis of six clinical trials

Revista Espanola de Quimioterapia

Volumn 21, Issue 1, 2008, Pages 14-21

  Granizo, J J ^a   Gimenez M J ^b   Barberan J ^c   Coronel, P ^d   Gimeno, M ^d   Aguilar, Lorenzo ^b  

^a Grana Datos   (Spain)

^b SCHOOL OF MEDICINE   (Spain)

^c HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^d Celltech Pharma   (Spain)

Author keywords

Cefditoren; Clinical trial; Pharyngotonsillitis; Pooled analysis; S. pyogenes; Sinusitis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFDITOREN; CEFUROXIME; PENICILLIN V; PENICILLIN V POTASSIUM;

ADOLESCENT; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIGESTIVE SYSTEM DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; MALE; OUTCOME ASSESSMENT; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINUSITIS; SKIN DISEASE; STREPTOCOCCUS PYOGENES; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT DISEASE;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 46049117039     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Llor C. Consideraciones a la hora de la prescripción antibiótica en atención primaria. Med Clin Monogr (Barc) 2004;5:52-7.
2. Mogyoros M. Challenges of managed care organisations in treating respiratory tract infections in an age of antibiotic resistance. Am J Man Care 2001;7(Suppl. 6):163-9.
3. Armstrong GL, Pinner RW. Outpatient visits for infectious diseases in the United States, 1980 through 1996. Arch Intern Med 1999;159:2531-6.
4. Linder JA, Stafford RS. Antibiotic treatment of adults with sore throat by community primary care physicians: a national survey, 1989-1999. JAMA 2001;286:1181-6.
5. Gwaltney JM Jr. Acute community-acquired sinusitis. Clin Infect Dis 1996;23:1209-23.
6. Hamory BH, Sande MA, Sydnor A Jr, Seale DL, Gwaltney JM Jr. Etiology and antimicrobial therapy of acute maxillary sinusitis. J Infect Dis 1979;139:197-202.
7. Perez-Trallero E, Montes M, Orden B, Tamayo E, García-Arenzana JM, Marimon JM. Phenotypic and genotypic characterization of Streptococcus pyogenes isolates displaying the MLSB phenotype of macrolide resistance in Spain, 1999 to 2005. Antimicrob Agents Chemother 2007;51:1228-33.
8. Perez-Trallero E, García de la Fuente C, García-Rey C, Baquero F, Aguilar L, Dal-Ré R, et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005;49:1965-72.
9. Pérez-Trallero E, Marimón JM, Ercibengoa M, Giménez MJ, Coronel P, Aguilar, L. Antimicrobial susceptibility of amoxicillin non-susceptible versus susceptible isolates among penicillin non-susceptible Streptococcus pneumoniae. Clin Microbiol Infect 2007;13:937-40.
10. García-Cobos S, Campos J, Lazaro E, Román F, Cercenado E, García-Rey C, et al. Ampicillin-resistant non-β-lactamase producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime. Antimicrob Agents Chemother 2007;51:2564-73.
11. Garcia-de-Lomas J, Lerma M, Cebrian L, Juan-Bañón JL, Coronel P, Giménez MJ, et al. Influence of Haemophilus influenzae beta-lactamase production and/or ftsl gene mutations on in vitro activity of and susceptibility rates to aminopenicillins and second-and third-generation cephalosporins. Int J Antimicrob Agents 2007;30:190-2.
12. Casey JR, Pichichero ME. The evidence base for cephalosporin superiority over penicillin in streptococcal pharyngitis. Diagn Microbiol Infect Dis 2007;57(3 Suppl.):S39-45.
13. Budhani RK, Struthers JK. Interaction of Streptococcus pneumoniae and Moraxella catarrhalis: investigation of the indirect pathogenic role of beta-lactamase-producing moraxellae by use of a continuous-culture biofilm system. Antimicrob Agents Chemother 1998;42:2521-6.
14. Fenoll A, Giménez MJ, Robledo O, Coronel P, Gimeno M, Casal J, et al. Activity of cefditoren against clinical isolates of Streptococcus pneumoniae showing non-susceptibility to penicillins, cephalosporins, macrolides, ketolides or quinolones. Int J Antimicrob Agents 2007;29:224-6.
15. Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials. Clin Ther 2006;28:2061-9.
16. Alvarez-Sala JL, Kardos P, Martínez-Beltrán J, Coronel P, Aguilar L. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother 2006;50:1762-7.
17. Kaplan EL, Tucker RM, Poling TL, Marsh D, Chow C. Managing group A streptococcal infection. A multicenter comparison of cefditoren pivoxil and penicillin VK. J Resp Dis 2001;22(8 Suppl.):S60-4.
18. Gooch W, Marsh D, Slickler T, Hunt B. Cefditoren is safe and effective treatment for streptococcal pharyngitis. In Abstracts of the fortyth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto 2000. Abstract 837. American Society for Microbiology. Washington, USA.
19. Chow J, Russell M, Volk S, Chow C. Efficacy of cefditoren pivoxil (CDTR) versus amoxicillin/clavulanate (AMX/CLV) in acute maxillary sinusitis (AMS). In Abstracts of the fortyth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto 2000, Abstract 835. American Society for Microbiology, Washington, USA.
20. Anzueto A, Bishai WR, Pottumarthy S. Role of oral extended-spectrum cephems in the treatment of acute exacerbation of chronic bronchitis. Diagn Microbiol Infect Dis 2007;57(3 Suppl.):S31-8.
21. Anon JB, Jacobs MR, Poole MD, Ambrose PG, Benninger MS, Hadley JA, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 130 (1 Suppl.):1-45.
22. Poole MD. Acute bacterial rhinosinusitis: clinical impact of resistance and susceptibility. Am J Med 2004;117(Suppl. 3A):29S-38S.
23. Desrosiers M, Klossek JM, Benninger M. Management of acute bacterial rhinosinusitis: current issues and future perspectives. Int J Clin Pract 2006;60:190-200.
24. Brook I, Foote PA. Efficacy of penicillin versus cefdinir in eradication of group A streptococci and tonsillar flora. Antimicrob Agents Chemother 2005;49:4787-8.
25. Brook I, Gober AE. Increased recovery of Moraxella catarrhalis and Haemophilus influenzae in association with group A beta-haemolytic streptococci in healthy children and those with pharyngo-tonsillitis. J Med Microbiol 2006;55:989-92.
26. Bisno AL. Are cephalosporins superior to penicillin for treatment of acute streptococcal pharyngitis? Clin Infect Dis 2004;38:1535-7.
27. Shulman ST, Gerber MA. So what's wrong with penicillin for strep throat? Pediatrics 2004;113:1816-9.
28. Casey JR, Pichichero ME. Meta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal tonsillopharyngitis in adults. Clin Infect Dis 2004;38:1526-34.
29. Brook I. A pooled comparison of cefdinir and penicillin in the treatment of group a beta-hemolytic streptococcal pharyngotonsillitis. Clin Ther 2005;27:1266-73.
30. Abdel-Haq NM, Harahsheh A, Asmar BL. Retropharyngeal abscess in children: the emerging role of group A beta hemolytic streptococcus. South Med J 2006;99:927-31.